Cornell University and The General Hospital Corp. (Massachusetts General Hospital) have synthesized conjugates comprising a targeting moiety covalently linked to a radiolabeled metal chelator through a linker acting as positron emission tomography (PET) or single-photon emission computerized tomography (SPECT) imaging agents reported to be useful for diagnosis and treatment of cancer.

Shenzhen Icarbonx Intelligent Peptide Pharmaceutical Technology Co. Ltd. has disclosed peptides targeting IQ motif and SEC7 domain-containing protein 1 (IQSEC1; BRAG2) reported to be useful for the treatment of stroke, major depression, substance abuse and dependence, and Alzheimer’s disease.

Boehringer Ingelheim Pharma GmbH & Co. KG has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, idiopathic pulmonary fibrosis, cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH), interstitial lung diseases, systemic scleroderma (systemic sclerosis) and systemic lupus erythematosus.

Schrodinger Inc. has divulged EGFR (HER1; erbB1) mutant inhibitors reported to be useful for the treatment of cancer.

Researchers at Dana Farber Cancer Institute Inc. and Stanford University have identified RAF proto-oncogene serine/threonine-protein kinase (RAF1; cRaf) inhibitors reported to be useful for the treatment of cancer.

Eli Lilly & Co. has synthesized relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of pulmonary hypertension, chronic obstructive pulmonary disease, acute kidney disease, chronic kidney disease, diabetic nephropathy and cardiovascular disorders, among others.

Kymera Therapeutics Inc. has disclosed signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, cardiovascular disorders, viral infections, neurodegeneration, and autoimmune, metabolic and liver diseases, among others.

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.

Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

Blossomhill Therapeutics Inc. has identified macrocyclic compounds reported to be useful for the treatment of cancer.